Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat Maintenance Post-HSCT for High-Risk AML and MDS
NCT04326764Phase 3Terminated
- Sponsor
- Goethe University Frankfurt
- Start
- Jul 2018
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of panobinostat in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Goethe University Frankfurt. Started Jul 2018; status: terminated.
02
Drugs
panobinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04326764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04326764.